INFORMATION FOR THE PRESS
Thank you for your interest.
Press registration for EULAR 2012 will open in early 2012.
If you have any queries for the Press Office, please contact us:
EULAR Media Officers:
Dimple Natali / Candice Debleu
eularpressoffice@uk.cohnwolfe.com
EULAR 2011 Press Releases
Embargotime is BST (British Summer Time)
Press Releases for 27.05.11
| Prof Nasim Khan | Embargotime: 09:00 (BST) | |
| STUDY REVEALS THAT FINANCIAL CONFLICTS OF INTEREST ARE ASSOCIATED WITH POSITIVE STUDY OUTCOMES | ||
| London, UK, Friday 27 May 2011: Randomised controlled trials (RCTs) of treatments for rheumatoid arthritis (RA) with authors receiving consulting fees/honoraria from the pharmaceutical industry have a significantly greater likelihood of reporting positive outcomes than RCTs without such financial conflicts of interest (FCOIs) according to data presented today at the EULAR 2011 Annual Congress. Results demonstrate that 91% of RCTs recording this kind of FCOI achieved a positive - outcome, compared to 66.7% of RCTs without specific FCOI (p=0.02) and adjusting for confounding factors did not change this finding. | ||
| View/Download this Press Release |  |
|
| Prof Aaron Juche | Embargotime: 09:00 (BST) | |
| THE USE OF PLACEBO IN RHEUMATOID ARTHRITIS CLINICAL TRIALS MAY NEGATIVELY IMPACT PATIENTS | ||
| London, UK, Friday 27 May 2011: Current study designs, assessing the effectiveness of new drugs for the treatment of rheumatoid arthritis (RA), discriminate against patients in the placebo-group, according to a critical appraisal assessing 17 trials, presented today at the EULAR 2011 Annual Congress. The authors of the study hypothesise that an active comparator group (i.e. current standard of care) should be used in all future new drug study designs as using placebo groups is not ethically acceptable. | ||
| View/Download this Press Release | |
|
| Prof Lene Dreyer | Embargotime: 09:00 (BST) | |
| LONG-TERM STUDY SHOWS THAT ARTHRITIS PATIENTS TAKING NEWER TREATMENTS DO NOT HAVE AN OVERALL INCREASED RISK OF CANCER | ||
| London, UK, Friday 27 May 2011: Newer biologic treatments, including infliximab (Remicade®), adalimumab (Humira®), certolizumab pegol (Cimzia®), golimumab (Simponi®) and etanercept (Enbrel®), used in patients with arthritis do not increase the risk of cancer, according to data from over 13,000 patients presented today at the EULAR 2011 Annual Congress. Only three percent (n=181) of patients in the study cohort receiving anti-tumour necrosis factor agents (anti-TNFs) for treatment of their arthritis developed a first cancer within nine years and overall risk was not dependent on the type of arthritis. | ||
| View/Download this Press Release | |
|
| Prof Jesper Lindhardsen | Embargotime: 09:00 (BST) | |
| UNDERTREATMENT OF CARDIOVASCULAR DISEASE OBSERVED IN RHEUMATOID ARTHRITIS PATIENTS FOLLOWING A HEART ATTACK | ||
| London, UK, Friday 27 May 2011: Following a first time myocardial infarction (MI or heart attack) patients with rheumatoid arthritis (RA) were significantly less likely to have been prescribed standard post-MI treatments than healthy controls, according to data presented today at the EULAR 2011 Annual Congress. The authors of the study hypothesise that clinicians may find that treatment of RA patients after a heart attack is more challenging than in healthy individuals. | ||
| View/Download this Press Release | |
|
Press Releases for 26.05.11
| Prof Sonia Panchal | Embargotime: 08:00 (BST) | |
| RHEUMATOLOGISTS AND OBSTETRICIANS PERSPECTIVE ON THE USE OF RHEUM DRUGS IN PREGNANCY | ||
| View/Download this Press Release | |
|
| Prof Ieda Laurindo | Embargotime: 08:00 (BST) | |
| PATIENTS WITH RA RECEIVE LESS PROTECTION FROM PANDEMIC INFLUENZA | ||
| View/Download this Press Release | |
|
| Prof Chi Chiu Mok | Embargotime: 08:00 (BST) | |
| STUDY SHOWS THE HPV VACCINE GARDASIL DOES NOT INCREASE DISEASE IN SLE PATIENTS | ||
| View/Download this Press Release | |
|
| Prof Fernando Perez-Ruiz | Embargotime: 08:00 (BST) | |
| SEVERAL ABSTRACTS ON GOUT REVEAL TRUE BURDEN OF DISEASE AND HIGHLIGHT NEW TREATMENTS | ||
| View/Download this Press Release | |
|
| Prof Howard Amital | Embargotime: 08:00 (BST) | |
| STUDY CONFIRMS LINK BETWEEN RA AND COPD | ||
| View/Download this Press Release | |
|
| Prof Katrina Thornely | Embargotime: 08:00 (BST) | |
| STUDIES SHOW SIGINIFICANT BENEFITS OF YOGA IN TWO CONDITIONS | ||
| London, UK, Thursday 26 May 2011: Individuals with Rheumatoid Arthritis (RA) who practice yoga showed statistically significant improvements in disease activity (DAS28*), according to a small study presented today at the EULAR 2011 Annual Congress. | ||
| View/Download this Press Release | |
|
| Mr Alexander Oldroyd | Embargotime: 08:00 (BST) | |
| THE DETRIMENTAL EFFECTS OF COELIAC DISEASE ON BONE MINERAL DENSITY ARE MORE PRONOUNCED IN THE LUMBAR SPINE THAN THE FEMORAL NECK | ||
| London, UK, Thursday 26 May 2011: Patients with coeliac disease are more than 4.5 times more likely to develop osteoporosis compared to healthy people in an age and gender matched cohort with no identifiable risk factors for osteoporosis, according to a study presented today at the EULAR 2011 Annual Congress. | ||
| View/Download this Press Release | |
|
| Prof Ninke Van Leeuwen | Embargotime: 08:00 (BST) | |
| THE INABILITY TO CRY IN PATIENTS WITH SJÖGRENS SYNDROME MAY ADVERSELY AFFECT EMOTIONAL AND MENTAL WELLBEING | ||
| London, UK, Thursday 26 May 2011: Patients with Sjögren s syndrome, a systemic immune disease which affects the production of tears and saliva, reported worse mental wellbeing and more difficulty in identifying feelings than the healthy population, according to results presented today at the EULAR 2011 Annual Congress. | ||
| View/Download this Press Release | |
|
Press Releases for 25.05.11
| No embargotime | ||
| EULAR 2011 PRESS ACTIVITIES PROGRAMME | ||
| View/Download this Press Release | |
|
| Prof Joel Kremer | No embargotime | |
| US STUDY SHOWS THAT TOFACITINIB IS AN EFFICACIOUS TREATMENT FOR ACTIVE RA WITH AN ACCEPTABLE SAFETY PROFILE | ||
| London, UK, Wednesday 25 May 2011: Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3% of patients who had previously not responded to treatment with DMARDs,* achieved ACR20** response (a 20% improvement in symptoms) when treated with the novel oral Janus kinase (JAK) inhibitor tofacitinib (CP-690,550) at 10mg BID compared to 31.2% in the placebo group. Significant improvements were also observed in the 5 mg BID dose. Most adverse events were mild and no new safety signals were reported, according to study authors. | ||
| View/Download this Press Release | |
|
| Prof Yusuf Yazici | No embargotime | |
| CHILDREN EXPERIENCE WRIST AND FINGER PAIN WHEN USING GAMING DEVICES AND MOBILE PHONES OVER TIME | ||
| London, UK, Wednesday 25 May 2011: For the first time, results on the impact of gaming devices on finger and wrist pain in children were presented today at the EULAR 2011 Annual Congress. Data comparing two schools in the USA demonstrate that young children experience high levels of pain following long term use of gaming devices and mobile phones indicating that excessive gaming may negatively impact on joint health. | ||
| View/Download this Press Release | |
|
| Prof Paul Emery | No embargotime | |
| TARGETED ADALIMUMAB TREATMENT CAN OPTIMISE LONG-TERM OUTCOMES FOR PATIENTS WITH EARLY RA | ||
| London, UK, Wednesday 25 May 2011: Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira®, ADA) plus methotrexate (MTX) in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some. | ||
| View/Download this Press Release | |
|
Related information
Press & Media Code of Practise
Activities of the press and media representatives are governed by the EULAR Press and Media Code of Practice.
Read Code of Practice for the Press >>
EULAR Abstract Embargo Policy
The publication of abstracts is ruled by the Abstract Embargo Policy.